Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 60(3): 1000-1017, 2017 02 09.
Article in English | MEDLINE | ID: mdl-28075591

ABSTRACT

Cyclophilin inhibition has been a target for the treatment of hepatitis C and other diseases, but the generation of potent, drug-like molecules through chemical synthesis has been challenging. In this study, a set of macrocyclic cyclophilin inhibitors was synthesized based on the core structure of the natural product sanglifehrin A. Initial compound optimization identified the valine-m-tyrosine-piperazic acid tripeptide (Val-m-Tyr-Pip) in the sanglifehrin core, stereocenters at C14 and C15, and the hydroxyl group of the m-tyrosine (m-Tyr) residue as key contributors to compound potency. Replacing the C18-C21 diene unit of sanglifehrin with a styryl group led to potent compounds that displayed a novel binding mode in which the styrene moiety engaged in a π-stacking interaction with Arg55 of cyclophilin A (Cyp A), and the m-Tyr residue was displaced into solvent. This observation allowed further simplifications of the scaffold to generate new lead compounds in the search for orally bioavailable cyclophilin inhibitors.


Subject(s)
Cyclophilins/antagonists & inhibitors , Cells, Cultured , Chromatography, Liquid , Crystallography, X-Ray , Drug Discovery , Humans , Hydrogen Bonding , Lactones/chemistry , Lactones/pharmacology , Proton Magnetic Resonance Spectroscopy , Spectrometry, Mass, Electrospray Ionization , Spiro Compounds/chemistry , Spiro Compounds/pharmacology , Structure-Activity Relationship , Surface Plasmon Resonance , Thermodynamics
2.
Invest Ophthalmol Vis Sci ; 48(9): 4107-15, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17724194

ABSTRACT

PURPOSE: Despite structural similarity with prostaglandin F(2 alpha), the ocular hypotensive agent bimatoprost (Lumigan; Allergan, Inc., Irvine, CA) shows unique pharmacology in vitro and functional activity in vivo. Unfortunately, the precise mechanisms that underlie bimatoprost's distinctive impact on aqueous humor dynamics are unclear. The purpose of the present study was to investigate the effects of bimatoprost and a novel prostamide-selective antagonist AGN 211334 on human conventional drainage. METHODS: Two model systems were used to test the consequences of bimatoprost and/or AGN 211334 treatment on conventional drainage. Human anterior segments in organ culture were perfused at a constant flow rate of 2.5 microL/min while pressure was recorded continuously. After stable baseline facilities were established, segments were treated with drug(s), and pressure was monitored for an additional 3 days. In parallel, the drugs' effects on hydraulic conductivity of human trabecular meshwork (TM) cell monolayers were evaluated. Pharmacological properties of AGN 211334 were characterized in isolated feline iris preparations in organ culture and heterologously expressed G-protein-coupled receptors were examined in vitro. RESULTS: Bimatoprost increased outflow facility by an average of 40% +/- 10% within 48 hours of treatment (n = 10, P < 0.001). Preincubation or coincubation with AGN 211334 significantly blunted bimatoprost's effects by 95% or 43%, respectively. Similar results were obtained in cell culture experiments in which bimatoprost increased hydraulic conductivity of TM cell monolayers by 78% +/- 25%. Pretreatment with AGN 211334 completely blocked bimatoprost's effects, while coincubation decreased its effects on average by 74%. In both models, AGN 211334 alone significantly decreased fluid flux across trabecular tissues and cells. CONCLUSIONS: The findings indicate that bimatoprost interacts with a prostamide receptor in the trabecular meshwork to increase outflow facility.


Subject(s)
Amides/pharmacology , Antihypertensive Agents/pharmacology , Cloprostenol/analogs & derivatives , Lipids/pharmacology , Trabecular Meshwork/drug effects , Aged , Aged, 80 and over , Amides/antagonists & inhibitors , Animals , Aqueous Humor/metabolism , Bimatoprost , Calcium/metabolism , Calcium Signaling/physiology , Cats , Cell Culture Techniques , Cloprostenol/antagonists & inhibitors , Cloprostenol/pharmacology , Dinoprost/pharmacology , Dinoprostone/analogs & derivatives , Dinoprostone/pharmacology , Female , Humans , Intraocular Pressure/physiology , Iris/drug effects , Lipids/antagonists & inhibitors , Male , Middle Aged , Muscle Contraction/physiology , Muscle, Smooth/drug effects , Organ Culture Techniques , Oxazoles/pharmacology , Receptors, Thromboxane/antagonists & inhibitors , Receptors, Thromboxane/metabolism , Recombinant Proteins , Trabecular Meshwork/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...